The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus
Journal of Diabetes and its Complications, cilt.22, sa.4, ss.241-245, 2008 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 22 Sayı: 4
- Basım Tarihi: 2008
- Doi Numarası: 10.1016/j.jdiacomp.2007.03.010
- Dergi Adı: Journal of Diabetes and its Complications
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.241-245
- Anahtar Kelimeler: diabetic neuropathy, pain, venlafaxine HCl
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The objective of this study was to evaluate the efficacy of venlafaxine HCl in the symptomatic treatment of painful peripheral diabetic neuropathy (PPDN) among patients with type 2 diabetes mellitus (DM). Design: This study was designed as a prospective, randomized, and controlled trial. Setting: This study was conducted at the Dicle University Medical Faculty (Diyarbakir, Turkey). Patients: Sixty type 2 DM outpatients (47 females and 13 males) with PPDN who had a minimum visual analog scale (VAS) score of 40 mm were enrolled in this study. Interventions: Patients randomized to the treatment group (n=30) received venlafaxine HCl, whereas those randomized to the control group (n=30) received a combination of vitamins B1and B6 tablets. Measures: Severity of pain was measured by VAS, Short-Form McGill Pain Questionnaire, and numerical analog scale scores at admission and at the second, fourth, and eighth weeks of the study. Polyneuropathy was supported by electromyelography. Outcome: In the treatment group, severity of pain was measured as 70.0±13.0 in the VAS, as 24.9±6.2 in the Short-Form McGill Pain Questionnaire, and as 7.2±1.1 in the numerical analog scale. In the control group, it was measured as 73.0±8.0 in the VAS, as 26.8±6.2 in the Short-Form McGill Pain Questionnaire, and as 7.4±0.8 in the numerical analog scale (P>.05). Results: The most common form of PPDN was distal symmetrical sensorimotor polyneuropathy in both groups (46.8% vs. 50.0%). At the end of the study, there was a significant difference in severity of pain between the groups. In the treatment group, scores were 8.5±5.2 and 3.1±1.6 in the Short-Form McGill Pain Questionnaire and numerical analog scale, respectively; in the control group, these were 20.5±7.0 and 5.5±1.6, respectively (P<.001). Conclusions: Venlafaxine HCl is a safe and well-tolerable analgesic drug in the symptomatic treatment of PPDN; however, it has minimal adverse effects. It showed its efficacy markedly in the second week of therapy. © 2008 Elsevier Inc. All rights reserved.